Zobrazeno 1 - 10
of 130
pro vyhledávání: '"Marleen, Kok"'
Autor:
Yuan Gao, Sofia Ventura-Diaz, Xin Wang, Muzhen He, Zeyan Xu, Arlene Weir, Hong-Yu Zhou, Tianyu Zhang, Frederieke H. van Duijnhoven, Luyi Han, Xiaomei Li, Anna D’Angelo, Valentina Longo, Zaiyi Liu, Jonas Teuwen, Marleen Kok, Regina Beets-Tan, Hugo M. Horlings, Tao Tan, Ritse Mann
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-17 (2024)
Abstract Multi-modal image analysis using deep learning (DL) lays the foundation for neoadjuvant treatment (NAT) response monitoring. However, existing methods prioritize extracting multi-modal features to enhance predictive performance, with limited
Externí odkaz:
https://doaj.org/article/c0d62ff4a3f64984a6d212ffdc266b26
Autor:
Josefien P. van Olmen, Veerle CM. Geurts, Marie-Jeanne TFD. Vrancken Peeters, Caroline A. Drukker, Marcel PM. Stokkel, Marleen Kok, Frederieke H. van Duijnhoven
Publikováno v:
Breast, Vol 78, Iss , Pp 103822- (2024)
Background: Guidelines recommend systemic therapy for stage I HER2+ breast cancer (BC). Neoadjuvant systemic treatment (NAST) allows response-guided adjuvant treatment. However, prior to NAST only clinical nodal staging is available, risking undertre
Externí odkaz:
https://doaj.org/article/c83b28677bb04a91a21da8b4b91658e4
Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial
Autor:
Mark Opdam, Annelot G.J. van Rossum, Marlous Hoogstraat, Gergana Bounova, Hugo M. Horlings, Erik van Werkhoven, Ingrid A.M. Mandjes, A. Elise van Leeuwen – Stok, Sander Canisius, Harm van Tinteren, Alex L.T. Imholz, Johanneke E.A. Portielje, Monique E.M.M. Bos, Sandra Bakker, Jelle Wesseling, Lennart Kester, Jacco van Rheenen, Emiel J. Rutgers, Renee X. de Menezes, Lodewyk F.A. Wessels, Marleen Kok, Hendrika M. Oosterkamp, Sabine C. Linn, Marcel Soesan, Rianne M. Oosterkamp, Frank Jeurissen, Nir Weijl, Karin J. Beelen, Aart van Bochove, Gerty de Klerk, Suzan Vrijaldenhoven, Annette van der Velden, Hiltje de Graaf, Marielle Smeets, Jetske Meerum Terwogt, Jolanda Schrama, Philomeen Kuijer, Hanneke Wilmink, Ronald Hoekstra, Judith Kroep, Hans F.M. Pruijt, Leander van Gerven, Allert H. Vos, Frans Erdkamp, Willemien G. van Leeuwen-Breuk, Alexander de Graeff
Publikováno v:
iScience, Vol 27, Iss 8, Pp 110425- (2024)
Summary: The primary objective of the prospective, randomized, multicenter, phase 3 biomarker Microarray Analysis in breast cancer to Taylor Adjuvant Drugs Or Regimens trial (MATADOR: ISRCTN61893718) is to generate a gene expression profile that can
Externí odkaz:
https://doaj.org/article/3dae747c44804a5fafa1281b33a3c21c
Autor:
Josefien P. van Olmen, Chaja F. Jacobs, Sanne A.L. Bartels, Claudette E. Loo, Joyce Sanders, Marie-Jeanne T.F.D. Vrancken Peeters, Caroline A. Drukker, Frederieke H. van Duijnhoven, Marleen Kok
Publikováno v:
Breast, Vol 75, Iss , Pp 103726- (2024)
Objective: This study aims to evaluate the response to and surgical benefits of neoadjuvant endocrine therapy (NET) in ER+/HER2-breast cancer patients who are clinically high risk, but genomic low risk according to the 70-gene signature (MammaPrint).
Externí odkaz:
https://doaj.org/article/704ad2649c1245a2bc5b540ca828061f
Autor:
Yuwei Wang, Gwen M. H. E. Dackus, Efraim H. Rosenberg, Sten Cornelissen, Leonora W. de Boo, Annegien Broeks, Wim Brugman, Terry W. S. Chan, Paul J. van Diest, Michael Hauptmann, Natalie D. ter Hoeve, Olga I. Isaeva, Vincent M. T. de Jong, Katarzyna Jóźwiak, Roelof J. C. Kluin, Marleen Kok, Esther Koop, Petra M. Nederlof, Mark Opdam, Philip C. Schouten, Sabine Siesling, Charlaine van Steenis, Adri C. Voogd, Willem Vreuls, Roberto F. Salgado, Sabine C. Linn, Marjanka K. Schmidt
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Background Due to the abundant usage of chemotherapy in young triple-negative breast cancer (TNBC) patients, the unbiased prognostic value of BRCA1-related biomarkers in this population remains unclear. In addition, whether BRCA1-related bio
Externí odkaz:
https://doaj.org/article/ddff242b9c864f39864f3885aee7bad4
Autor:
Tessa G. Steenbruggen, Denise M. Wolf, Michael J. Campbell, Joyce Sanders, Sten Cornelissen, Bram Thijssen, Roberto A. Salgado, Christina Yau, Nick O-Grady, Amrita Basu, Rajith Bhaskaran, Lorenza Mittempergher, Gillian L. Hirst, Jean-Philippe Coppe, Marleen Kok, Gabe S. Sonke, Laura J. van ‘t Veer, Hugo M. Horlings
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-19 (2023)
Abstract Background Despite major improvements in treatment of HER2-positive metastatic breast cancer (MBC), only few patients achieve complete remission and remain progression free for a prolonged time. The tumor immune microenvironment plays an imp
Externí odkaz:
https://doaj.org/article/cd4ee360474c49639be138517e337159
Autor:
Leonie Voorwerk, Joyce Sanders, Milou S. Keusters, Sara Balduzzi, Sten Cornelissen, Maxime Duijst, Esther H. Lips, Gabe S. Sonke, Sabine C. Linn, Hugo M. Horlings, Marleen Kok
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-10 (2023)
Abstract Immune checkpoint blockade (ICB) is currently approved for patients with triple-negative breast cancer (TNBC), whereas responses to ICB are also observed in a small subgroup of Estrogen Receptor (ER)-positive breast cancer. The cut-off for E
Externí odkaz:
https://doaj.org/article/bf1f76273f634aa69a34a1e2029a1773
Autor:
Olga S. Blomberg, Kevin Kos, Lorenzo Spagnuolo, Olga I. Isaeva, Hannah Garner, Max D. Wellenstein, Noor Bakker, Danique E.M. Duits, Kelly Kersten, Sjoerd Klarenbeek, Cheei-Sing Hau, Daphne Kaldenbach, Elisabeth A.M. Raeven, Kim Vrijland, Marleen Kok, Karin E. de Visser
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTThe clinical successes of immune checkpoint blockade (ICB) in advanced cancer patients have recently spurred the clinical implementation of ICB in the neoadjuvant and perioperative setting. However, how neoadjuvant ICB therapy affects the sys
Externí odkaz:
https://doaj.org/article/b656e036ddb5458b8a3bb50ca339a61b
Autor:
Yin Wu, Charles Swanton, Mihaela Angelova, Crispin Hiley, Marleen Kok, Nicolai Birkbak, Ieva Usaite, Dhruva Biswas, Krijn Dijkstra, Thomas BK Watkins, Oriol Pich, Clare Puttick, Krupa Thakkar, Simone Zaccaria, Kevin Litchfield, Nnennaya Kanu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 11 (2023)
Background Checkpoint inhibitor (CPI) immunotherapies have provided durable clinical responses across a range of solid tumor types for some patients with cancer. Nonetheless, response rates to CPI vary greatly between cancer types. Resolving intratum
Externí odkaz:
https://doaj.org/article/da17de2de8c74189b560015ef1154a8e
Autor:
Khalid El Bairi, Harry R. Haynes, Elizabeth Blackley, Susan Fineberg, Jeffrey Shear, Sophia Turner, Juliana Ribeiro de Freitas, Daniel Sur, Luis Claudio Amendola, Masoumeh Gharib, Amine Kallala, Indu Arun, Farid Azmoudeh-Ardalan, Luciana Fujimoto, Luz F. Sua, Shi-Wei Liu, Huang-Chun Lien, Pawan Kirtani, Marcelo Balancin, Hicham El Attar, Prerna Guleria, Wenxian Yang, Emad Shash, I-Chun Chen, Veronica Bautista, Jose Fernando Do Prado Moura, Bernardo L. Rapoport, Carlos Castaneda, Eunice Spengler, Gabriela Acosta-Haab, Isabel Frahm, Joselyn Sanchez, Miluska Castillo, Najat Bouchmaa, Reena R. Md Zin, Ruohong Shui, Timothy Onyuma, Wentao Yang, Zaheed Husain, Karen Willard-Gallo, An Coosemans, Edith A. Perez, Elena Provenzano, Paula Gonzalez Ericsson, Eduardo Richardet, Ravi Mehrotra, Sandra Sarancone, Anna Ehinger, David L. Rimm, John M. S. Bartlett, Giuseppe Viale, Carsten Denkert, Akira I. Hida, Christos Sotiriou, Sibylle Loibl, Stephen M. Hewitt, Sunil Badve, William Fraser Symmans, Rim S. Kim, Giancarlo Pruneri, Shom Goel, Prudence A. Francis, Gloria Inurrigarro, Rin Yamaguchi, Hernan Garcia-Rivello, Hugo Horlings, Said Afqir, Roberto Salgado, Sylvia Adams, Marleen Kok, Maria Vittoria Dieci, Stefan Michiels, Sandra Demaria, Sherene Loi, The International Immuno-Oncology Biomarker Working Group
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-17 (2021)
Abstract The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of pr
Externí odkaz:
https://doaj.org/article/98d18f7227c34bcb8909cccb39302c30